Exopharm Limited (EX1)
20mins delayed
Movement
1 Year Return
Exopharm Limited Chart
| Share price | |
| Last | |
| Change | |
| Volume | |
| Turnover | |
| Market Cap | $22.13 million |
| Today's Movement | |
| Prev. Close | |
| Open | |
| Day Range | - |
| VWAP | |
| Historical Stats | |
| 52w Range | - |
| 4w Avg Volume | |
| 4w Avg Turnover | |
| (delayed) | |
EX1 Statistics
13 November
1,409 / 2,298
ASX Size Rank
1yr Return
vs Sector (1yr)
-66.00%
vs ASX 200 (1yr)
-43.66%
$22.13 million
Market Cap
Share Issue
59.81 million
All Ords (%)
N/A
Short Sold
0%
Current Fundamentals
13 November
N/A
PE Ratio
EPS ($)
-0.04
Earnings Yield
-10.89%
NTA ($)
0.09
N/A
Dividend Yield
DPS ($)
-
Gross Div. Yield
-
Gross DPS ($)
-
Company Overview
Exopharm Limited (EX1) operates in the healthcare sector, specifically in the regenerative medicine industry. As its primary focus, Exopharm aims to be a leader in the field of clinical human therapeutics using exosomes as regenerative medicine products. Exopharm seeking to develop and commercialise exosomes as therapeutic agents – initially a product called Plexaris and later as a product called Exomeres. These products are exosomes that are derived from human platelets in relation to Plexaris, and adult stem cells in relation to Exomeres, and purified using the LEAP Technology and referred to as biologic products. Exopharm's key asset is the LEAP Technology (which includes the Patent Applications) and associated know-how.
Upcoming Calendar
Dividend History
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| No dividends paid in the last 5 years | ||||
See Upcoming Dividends for all ASX companies.
Announcements
| Date | Heading | Pages | File Size | Time |
|---|---|---|---|---|
Broker Consensus
The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.
EX1 is not covered by a major broker.
Directors & Management
| Name | Title | Since | Bio |
|---|---|---|---|
| Mr David Rodney Parker | Company Secretary, Non-Executive Director | Jun 2018 |
|
| Dr Ian Edward Dixon | Company Founder, Technology Co-Founder, Managing Director | May 2013 |
|
| Mr Jason Mark Watson | Non-Executive Chairman, Non-Executive Director | Aug 2018 |
|
Director Transactions
EX1 directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
| Date | Director | Type | Amount | Price | Value | Notes |
|---|---|---|---|---|---|---|
| 13/09/19 | Jason Watson | Issued | 100,000 | $0.370 | $37,000 | Placement. |
| 19/08/19 | David Parker | Buy | +20,000 | $0.370 | $7,400 | Participation in share purchase plan. |
| 19/08/19 | Ian Dixon | Buy | +40,000 | $0.370 | $14,800 | Participation in share purchase plan. |
| 19/08/19 | Jason Watson | Buy | +40,000 | $0.370 | $14,800 | Participation in share purchase plan. |
Shareholder Distribution
| Holding Size | 1 - 1,000 | 1,001 - 5,000 | 5,001 - 10,000 | 10,001 - 100,000 | 100,001 and over | Total Shareholders |
|---|---|---|---|---|---|---|
| No. of Shareholders | 21 | 80 | 125 | 549 | 166 | 941 |
Top 20 Shareholders
| Name | Shares | Capital |
|---|---|---|
| Altnia Holdings Pty Ltd (Dixon Family A/C) | 27,975,294 | 29.33% |
| Mr Michael Francis Mcmahon & Mrs Susan Lesley Mcmahon (Mcmahon Super Fund A/C) | 2,310,000 | 2.42% |
| Oldview Enterprises Pty Ltd (The Priestley A/C) | 1,476,963 | 1.55% |
| Anthony John Locantro | 1,330,000 | 1.39% |
| Carda Pty Ltd (Carda Super Fund A/C) | 1,220,000 | 1.28% |
| Phytose Corporation Pty Limited (Boundaryone Super A/C) | 1,176,471 | 1.23% |
| Pabasa Pty Ltd (Kehoe Family Super Fund A/C) | 1,000,000 | 1.05% |
| Mrs Anna Felicia Belton | 978,334 | 1.03% |
| Acns Capital Markets Pty Ltd | 810,000 | 0.85% |
| Drp 2006 Super Pty Ltd (Drp (2006) Super Fund A/C) | 760,000 | 0.80% |
| Basapa Pty Ltd (Kehoe Family A/C) | 750,000 | 0.79% |
| Kohen Enterprises Pty Ltd | 750,000 | 0.79% |
| Lonhro (Wa) Pty Ltd (Lonhro A/C) | 736,667 | 0.74% |
| Saintly Company Pty Ltd (Walker Investment A/C) | 670,000 | 0.70% |
| Mr Andrew Stewart Coles & Ms Alexandra Constance Manook (Coles Family Super A/C) | 615,000 | 0.64% |
| Gregor Lichtfuss | 588,235 | 0.62% |
| Mr Anthony De Nicola & Mrs Tanya Louise De Nicola (De Nicola Family S/F A/C) | 575,000 | 0.60% |
| Jeccs Pty Ltd (Brown Family No1 A/C) | 547,000 | 0.57% |
| Labonne Enterprises Pty Ltd (Mcintyre Family A/C) | 500,000 | 0.52% |
| Ringsford Pty Ltd (Dg & Gl Walker S/F A/C) | 500,000 | 0.52% |
| All other shareholders | 52.58 % | |
The Top 20 Shareholders of EX1 hold 47.42% of shares on issue.
EX1 Share Price History
| Date | Close | Change | % Change | Open | High | Low | Volume | Turnover |
|---|---|---|---|---|---|---|---|---|
EX1 Historical Data
Download up to 20 years of share price history.
| Year | Closing Price (30 June) | Last Trade |
|---|
Offical data as published by ASX. See more Data Downloads.
Company Details
Principal Activity: Developing regenerative medicine, primarily being the development and de-risking of exosome technologies, particularly the LEAP manufacturing process and development of the Plexaris and Exomere products.
Incorporated: --
Level 17, 31 Queen St
Melbourne VIC 3000
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.